JonesTrading analyst Soumit Roy has reiterated their bullish stance on CGON stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Soumit Roy has given his Buy rating due to a combination of factors surrounding CG Oncology’s promising data on their bladder cancer treatment. The company’s oncolytic immunotherapy, cretostimogene, has shown impressive results in treating high-grade non-muscle invasive bladder cancer (NMIBC), particularly in the BCG-Naive and BCG-Unresponsive settings. The treatment demonstrated a higher complete response rate when the administration protocol was shortened, outperforming competitors and standard care options.
Moreover, cretostimogene has shown superior event-free survival in challenging patient groups, reinforcing its efficacy across various NMIBC settings. The positive data readouts have addressed previous concerns about the drug’s performance outside specific settings and its safety profile. With ongoing trials and future data readouts expected, there is optimism about cretostimogene’s potential to expand its application and further solidify its market position, justifying the Buy rating.